Aclaris Therapeutics Management
Management criteria checks 3/4
Aclaris Therapeutics' CEO is Neal Walker, appointed in Jul 2012, has a tenure of 13.5 years. total yearly compensation is $1.47M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 1.38% of the company’s shares, worth $6.63M. The average tenure of the management team and the board of directors is 2 years and 11.3 years respectively.
Key information
Neal Walker
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 32.55% |
| CEO tenure | 13.5yrs |
| CEO ownership | 1.4% |
| Management average tenure | 2yrs |
| Board average tenure | 11.3yrs |
Recent management updates
Recent updates
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 25% Share Price Surge Not Quite Adding Up
Dec 19
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 31%
Oct 31Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Deliver On Growth Plans?
Sep 04Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates
Aug 10Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26%
Jun 12Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?
May 21Some Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shareholders Look For Exit As Shares Take 31% Pounding
Apr 23Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Mar 07Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule
Feb 11Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 12Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$142m |
| Jun 30 2025 | n/a | n/a | -US$135m |
| Mar 31 2025 | n/a | n/a | -US$130m |
| Dec 31 2024 | US$1m | US$477k | -US$132m |
| Sep 30 2024 | n/a | n/a | -US$37m |
| Jun 30 2024 | n/a | n/a | -US$59m |
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$74k | n/a | -US$88m |
| Sep 30 2023 | n/a | n/a | -US$115m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$96m |
| Dec 31 2022 | US$6m | US$590k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$7m | US$567k | -US$91m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$71m |
| Mar 31 2021 | n/a | n/a | -US$65m |
| Dec 31 2020 | US$2m | US$424k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$57m |
| Jun 30 2020 | n/a | n/a | -US$69m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$3m | US$500k | -US$114m |
Compensation vs Market: Neal's total compensation ($USD1.47M) is below average for companies of similar size in the US market ($USD2.28M).
Compensation vs Earnings: Neal's compensation has increased whilst the company is unprofitable.
CEO
Neal Walker (55 yo)
Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.5yrs | US$1.47m | 1.38% $ 6.6m | |
| President | 1.2yrs | US$2.06m | 0.025% $ 118.2k | |
| Chief Financial Officer | 3yrs | US$1.10m | 0.15% $ 709.0k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior VP of Corporate Communications & Investor Relations | 1yr | no data | no data | |
| General Counsel & Corporate Secretary | 3.6yrs | no data | no data | |
| Senior Vice President of Chemistry | no data | no data | no data | |
| Chief Business Officer | 4yrs | US$2.33m | 0.14% $ 685.3k | |
| Executive Vice President of Project Leadership | 2yrs | no data | no data | |
| Senior Vice President of Clinical Development | 2yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Senior Vice President of Clinical Operations | 1.1yrs | no data | no data |
Experienced Management: ACRS's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.5yrs | US$1.47m | 1.38% $ 6.6m | |
| President | 1.2yrs | US$2.06m | 0.025% $ 118.2k | |
| Independent Director | 6yrs | US$73.32k | 0.016% $ 76.5k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 11.3yrs | US$87.32k | 0.66% $ 3.2m | |
| Member of Advisory Board | no data | no data | no data | |
| Lead Independent Director | 12yrs | US$96.07k | 0.053% $ 256.2k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data |
Experienced Board: ACRS's board of directors are seasoned and experienced ( 11.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/22 23:02 |
| End of Day Share Price | 2026/01/22 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aclaris Therapeutics, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Donald Ellis | Citizens JMP Securities, LLC |